JulieRuggieriParkMD(She/Her)

Pediatric Hematology & Oncology • Seattle, WA

Full Member, and Chair Department of Oncology St. Jude Children's Research Hospital

Join to view full profile

Dr. Park is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Park's full profile

Already have an account?

Office
4800 Sand Point Way Ne
Seattle, WA 98105
Phone+1 206-987-2000
Is this information wrong?

Education & Training

University of WashingtonFellowship, Pediatric Hematology/Oncology, 1991 - 1994
University of WashingtonResidency, Pediatrics, 1988 - 1991
University of Vermont College of MedicineClass of 1988

Certifications & Licensure

TN State Medical License 2023 - 2025
WA State Medical License 1988 - 2023
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
America's Top Doctors for Cancer Castle Connolly, 2011-2013

Clinical Trials

N99-02: Melphalan and Buthionine Sulfoximine Start of enrollment: 2001 Aug 01
Completed
Phase 1
Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma Start of enrollment: 2000 May 01
Completed
Phase 1
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Start of enrollment: 2001 Feb 01
Unknown status
Phase 3
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Start of enrollment: 2004 Mar 15
Completed
Phase 3
Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma Start of enrollment: 2004 Mar 01
Completed
Phase 1
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Start of enrollment: 2004 Sep 04
Completed
Phase 3
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Start of enrollment: 2004 Mar 25
Recruiting
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Start of enrollment: 2004 Apr 01
Active, not recruiting
Phase 3
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Start of enrollment: 2005 Nov 14
Completed
Phase 3
Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission Start of enrollment: 2005 May 30
Completed
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma Start of enrollment: 2005 Dec 01
Completed
Phase 1
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Start of enrollment: 2007 May 03
Completed
Phase 3
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant Start of enrollment: 2006 Apr 01
Completed
Phase 2
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Start of enrollment: 2006 Jun 01
Completed
Phase 2
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Start of enrollment: 2007 Aug 06
Active, not recruiting
Phase 3
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias Start of enrollment: 2006 May 01
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Start of enrollment: 2006 Oct 30
Active, not recruiting
Phase 3
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Start of enrollment: 2006 Dec 26
Completed
Phase 3
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Start of enrollment: 2007 Mar 01
Completed
Phase 3
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Start of enrollment: 2007 Mar 01
Completed
Phase 1, Phase 2
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Start of enrollment: 2007 Feb 26
Active, not recruiting
Phase 3
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission Start of enrollment: 2007 Mar 01
Completed
Phase 3
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Start of enrollment: 2007 Mar 26
Active, not recruiting
Phase 3
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Start of enrollment: 2007 Jan 22
Active, not recruiting
Phase 3
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia Start of enrollment: 2007 Jan 01
Completed
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin Start of enrollment: 2007 May 01
Completed
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma Start of enrollment: 2007 Nov 05
Completed
Phase 3
N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma Start of enrollment: 2006 Dec 01
Completed
Phase 1
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System Start of enrollment: 2008 Dec 08
Active, not recruiting
Phase 3
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Start of enrollment: 2008 Apr 01
Completed
Phase 2
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
Recruiting
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2009 Jan 01
Completed
Phase 2
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Start of enrollment: 2009 Mar 09
Completed
Phase 3
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment Start of enrollment: 2009 Apr 01
Completed
Phase 1
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma Start of enrollment: 2009 Dec 01
Completed
Phase 1
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2006 Sep 25
Completed
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Completed
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma Start of enrollment: 2008 Feb 04
Completed
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma Start of enrollment: 2008 Feb 04
Completed
Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma Start of enrollment: 2006 Oct 23
Completed
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Start of enrollment: 2004 Feb 16
Completed
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment Start of enrollment: 2009 Jun 01
Completed
Phase 1
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia Start of enrollment: 2009 Jun 01
Terminated
Phase 1
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Start of enrollment: 2009 Sep 21
Completed
Phase 1, Phase 2
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Study of Blood Samples From Newborns With Down Syndrome Start of enrollment: 2009 Feb 23
Completed
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 3
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma Start of enrollment: 2005 May 30
Completed
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma Start of enrollment: 2010 Mar 01
Completed
Phase 1
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2009 Dec 21
Completed
Phase 3
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Start of enrollment: 2009 Sep 01
Completed
Phase 1
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Start of enrollment: 2010 Jan 01
Completed
Phase 2
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
Active, not recruiting
Phase 3
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2010 Jun 01
Completed
Phase 1
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Start of enrollment: 2011 Feb 01
Completed
Phase 2
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Start of enrollment: 2010 Sep 01
Completed
Phase 1
Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Start of enrollment: 2010 Aug 09
Completed
Phase 1, Phase 2
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma Start of enrollment: 2010 Dec 01
Completed
Phase 1
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Start of enrollment: 2010 Oct 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
Active, not recruiting
Phase 3
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Start of enrollment: 2011 Jan 01
Completed
Phase 1
Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2010 Dec 01
Completed
Phase 1
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Start of enrollment: 2012 Jan 01
Completed
Phase 2
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2012 Nov 14
Completed
Phase 1
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma Start of enrollment: 2013 Feb 04
Active, not recruiting
Phase 1
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Start of enrollment: 2013 Nov 01
Completed
Phase 1
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Start of enrollment: 2013 Sep 03
Completed
Phase 1
Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors Start of enrollment: 2013 Dec 01
Unknown status
Not Applicable
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16
Active, not recruiting
Phase 1
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2014 Mar 28
Completed
Phase 1, Phase 2
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Start of enrollment: 2014 May 16
Completed
Phase 1, Phase 2
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01
Completed
Phase 1
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11
Completed
Phase 1
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Start of enrollment: 2016 Dec 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study.
Cohn, S. L., Erica C Kaye, Jesse Smith, Yiwang Zhou, Rochelle Bagatell, Justin N Baker, Susan L Cohn, Lisa R Diller, Julia L Glade Bender, M Meaghan Granger, Araz Mara...> ;Cancer. 2024 Apr 1
Topotecan clearance based on a single sample and a population pharmacokinetic model: Application to a pediatric high-risk neuroblastoma clinical trial.
Olivia Campagne, Huiyun Wu, Jianrong Wu, Arlene Naranjo, Vinay M Daryani, Amar J Gajjar, Julie R Park, Clinton F Stewart> ;Pediatric Blood & Cancer. 2023 Nov 1
1 citations
Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report f...
Keri A Streby, Marguerite T Parisi, Barry L Shulkin, Brian LaBarre, Rochelle Bagatell, Lisa Diller, Stephan A Grupp, Katherine K Matthay, Stephan D Voss, Alice L Yu, W...> ;Pediatric Blood & Cancer. 2023 Aug 1
3 citations
Children's Oncology Group's 2023 blueprint for research: Neuroblastoma.
Rochelle Bagatell, Steven G DuBois, Arlene Naranjo, Jen Belle, Kelly C Goldsmith, Julie R Park, Meredith S Irwin> ;Pediatric Blood & Cancer. 2023 Sep 1
4 citations
Access to Chimeric Antigen Receptor T Cell Clinical Trials in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult Acute Lymphobastic ...
Anurekha G Hall, Lena E Winestone, Erin M Sullivan, Qian Wu, Adam J Lamble, Mark C Walters, Paibel Aguayo-Hiraldo, Lourdes Baez Conde, Tumaini R Coker, Dana Dornsife, ...> ;Transplantation and Cellular Therapy. 2023 Jun 1
54 citations
Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety.
Nicholas A Vitanza, Ashley L Wilson, Wenjun Huang, Kristy Seidel, Christopher Brown, Joshua A Gustafson, Jason K Yokoyama, Adam J Johnson, Blake A Baxter, Ryan W Konin...> ;Cancer Discovery. 2023 Jan 9
7 citations
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
Ami V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, Arlene Naranjo, Wendy B London, Sheena C Tenney, Mitchell Diccianni, Jacquelyn A Hank, Marguerite T Parisi, Barry ...> ;Journal of Clinical Oncology. 2022 Dec 10
2 citations
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National...
Julie R Park, Judith G Villablanca, Barbara Hero, Brian H Kushner, Keith Wheatley, Klaus H Beiske, Ruth L Ladenstein, Sylvain Baruchel, Margaret E Macy, Lucas Moreno, ...> ;Cancer. 2022 Nov 1
5 citations
Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects.
Francesco Ceppi, Ashley L Wilson, Colleen Annesley, Gabriella R Kimmerly, Corinne Summers, Adam Brand, Kristy Seidel, Qian Vicky Wu, Adam Beebe, Christopher Brown, Ste...> ;Cancer Immunology Research. 2022 Jul 1
Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy.
Shahab Asgharzadeh, Araz Marachelian, Judith G Villablanca, Wei Yao Liu, Rebekah Kennedy, Richard Sposto, Arlene Naranjo, Sheena Tenney, Alice L Yu, M Fevzi Ozkaynak, ...> ;Pediatric Blood & Cancer. 2022 Sep 1
26 citations
Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Lymphoma Remission Confers a Leukemia-Free Survival Advantage.
Corinne Summers, Qian Vicky Wu, Colleen Annesley, Marie Bleakley, Ann Dahlberg, Prabha Narayanaswamy, Wenjun Huang, Jenna M. Voutsinas, Adam Brand, Wendy M. Leisenring...> ;Transplantation and Cellular Therapy. 2021 Oct 10
32 citations
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Ag...
Andrew D.J. Pearson, Elly Barry, Yael P. Mosse, Franca Ligas, Nick Bird, Teresa de Rojas, Zachary Franklin Zimmerman, Keith D. Wilner, Willi Woessmann, Susan L. Weiner...> ;European Journal of Cancer. 2021 Sep 15
142 citations
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.
Meredith S. Irwin, Arlene Naranjo, Fan F Zhang, Susan L. Cohn, Wendy B. London, Julie M. Gastier-Foster, Nilsa C. Ramirez, Ruthann Pfau, Shalini C. Reshmi, Elizabeth W...> ;Journal of Clinical Oncology. 2021 Jul 28
25 citations
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report ...
Steven G. DuBois, M. Meaghan Granger, Susan Groshen, Denice D. Tsao-Wei, Lingyun Ji, Anasheh Shamirian, Scarlett Czarnecki, Fariba Goodarzian, Rachel Berkovich, Hiroyu...> ;Journal of Clinical Oncology. 2021 Jul 16
122 citations
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis
Nicholas A Vitanza, Adam Johnson, Ashley Wilson, Christopher Brown, Jason K. Yokoyama, Annette Künkele, Cindy A. Chang, Stephanie Rawlings-Rhea, Wenjun Huang, Kristy S...> ;Nature Medicine. 2021 Jul 12
4 citations
Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma.
Skye Balyasny, Sang Mee Lee, Ami V. Desai, Samuel L. Volchenboum, Arlene Naranjo, Julie R. Park, Wendy B. London, Susan L. Cohn, Mark A. Applebaum> ;JAMA Network Open. 2021 Jul 1
8 citations
A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study.
Brian Weiss, Gregory A. Yanik, Arlene Naranjo, Fan F Zhang, Wendy Fitzgerald, Barry L. Shulkin, Marguerite T. Parisi, Heidi V. Russell, Stephan A. Grupp, Luke Pater, P...> ;Pediatric Blood & Cancer. 2021 May 24
11 citations
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Tr...
M. Meaghan Granger, Arlene Naranjo, Rochelle Bagatell, Steven G. DuBois, Jeannine S. McCune, Sheena C. Tenney, Brian Weiss, Yael P. Mosse, Shahab Asgharzadeh, S. Grupp...> ;Transplantation and Cellular Therapy. 2021 Jun 1
19 citations
Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers
Adam J. Wolpaw, Richard Bayliss, Gabriele Büchel, Chi V. Dang, Martin Eilers, W. Clay Gustafson, Gwenn H. Hansen, Natalia Jura, Stefan Knapp, Mark A. Lemmon, David Lev...> ;Cancer Research. 2021 Jan 28
78 citations
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
Alice L. Yu, Andrew L. Gilman, M. Fevzi Ozkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan, Jacquelyn A. Hank, Ayse Batova, Wendy B. London, Sheena C. Tenney, ...> ;Clinical Cancer Research. 2021 Apr 15
5 citations
Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From...
Asuka Kawano, Florette K. Hazard, Bill Chiu, Arlene Naranjo, Brian LaBarre, Wendy B. London, Michael D. Hogarty, Susan L. Cohn, John M. Maris, Julie R. Park, Julie M. ...> ;The American Journal of Surgical Pathology. 2021 Aug 1
27 citations
Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer.
Jennifer W. Mack, Hajime Uno, Clare J. Twist, Rochelle Bagatell, Abby R. Rosenberg, Araz Marachelian, M. Meaghan Granger, Julia Glade Bender, Justin N. Baker, Julie R....> ;Journal of Pain and Symptom Management. 2020 Oct 1
Reply to K. Beiske et al
Elizabeth A. Sokol, Ami V. Desai, Mark A. Applebaum, Dominique Valteau-Couanet, Julie R. Park, Andrew D.J. Pearson, Gudrun Schleiermacher, Meredith S. Irwin, Michael D...> ;Journal of Clinical Oncology. 2020 Sep 15
6 citations
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG T...
Inge M. Ambros, Gian-Paolo Tonini, Ulrike Pötschger, Nicole Gross, Véronique Mosseri, Klaus Beiske, Ana P. Berbegall, Jean Bénard, Nick Bown, Huib N. Caron, Valérie Co...> ;Journal of Clinical Oncology. 2020 Sep 9
30 citations
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer...
Lucas Moreno, Giuseppe Barone, Steven G. DuBois, Jan J. Molenaar, Matthias Fischer, Johannes H. Schulte, Angelika Eggert, Gudrun Schleiermacher, Frank Speleman, Louis ...> ;European Journal of Cancer. 2020 Sep 1
Join now to see all

Abstracts/Posters

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo
Julie R. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses
Julie R. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

FDA Committee Unanimously Rejects 131-I-Omburtamab for NeuroblastomaOctober 28th, 2022
Practice-Changing Trial in Neuroblastoma, but Questions RemainAugust 27th, 2019
74 Oncologists on the MoveOctober 11th, 2023

Grant Support

COG Advl0419: Valproic Acid In Children With Recurrent/Progressive Solid TumorsNational Center For Research Resources2007
COG Advl0416: A Phase 1 Study Of SAHA In Pediatric Patients With RecurrentNational Center For Research Resources2007
COG Advl0413: A Phase I Study Of The RAF Kinase And Receptor Tyrosine KinaseNational Center For Research Resources2007
NANT 2004-01: A Phase I Study Of Zoledronic Acid (ZOMETA) With CyclophosphamideNational Center For Research Resources2006–2007
NANT 2003-01: A Phase I Study Of Oral Irinotecan, Temozolomide, And CefiximeNational Center For Research Resources2006–2007
Advl0319 Phase I Study Of CC-5013 (LENALIDOMIDE) In Pediatric PatientsNational Center For Research Resources2006–2007
NANT 2001-03: Phase 1 Study Of CEP-701 In Patients With Refractory NeuroblastomaNational Center For Research Resources2004–2007
COG Advl0416: A Study Of SAHA In Pediatric Patients Wth Recurrent Solid TumorsNational Center For Research Resources2006
COG Advl0317: A Phase I Study Of PS-341 (Velcade, Bortezomiv) In Ped PatientsNational Center For Research Resources2006
COG Advl0316: A Phase I Study Of 17-AAG In Relapsed/Refractory PediatricNational Center For Research Resources2006
COG Advl0214: A Phase I Study Of Single Agent OSI-774 (TARCEVA)National Center For Research Resources2006
COG Advl0314: A Phase 1 Study Of Bevacizumab In Refractory Solid TumorsNational Center For Research Resources2005–2006
NANT 2002-01 Phase 1 Study Of High Dose Pyrasolacridine (Pza)(Nsc 366140) SupporNational Center For Research Resources2004–2006
Novel Therapies For High-Risk NeuroblastomaNational Cancer Institute2002–2006
Cog-Anbl02p1: A Pilot Induction Regimen Incorporating Topotecan For Treatment ONational Center For Research Resources2005
Cog-Advl0311: Pemetrexed In Children And Adolescents With Recurrent Solid TumorsNational Center For Research Resources2005
COG Advl0316: 17-AAG In Pediatric Patients With Solid Tumors Or LeukemiaNational Center For Research Resources2005
COG Advl0215: Decitabine In Combination With Doxorubicin And CyclophosphamideNational Center For Research Resources2005
COG Advl0211: G3139 With Cytotoxic Chemotherapy In Relapsed Childhood TumorsNational Center For Research Resources2005
Cog-Anbl0321: A Phase II Study Of Fenretinide (Nsc #374551, IND #40294) In ChiaNational Center For Research Resources2004
COG Advl0215: A Phase I Study Of Decitabine (Nsc #127716, IND #50733) In CombinNational Center For Research Resources2004
COG Advl0212 - A Phase I Study Of Depsipeptide (Nsc # 630176, IND # 51810) In PSNational Center For Research Resources2004
COG Advl0211 - A Phase I Trial Of G3139 (Bcl-2 Antisense, NSC# 683428, Ind# 588sNational Center For Research Resources2004
Ccg-A0981, A Phase I Intergroup Trial Of The Hu14.18-Il2 Fusion Protein In ChilsNational Center For Research Resources2004